Drugs / Calcium (13C)Carbonate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03284177 | Oct 2017 → Dec 2018 | gastroesophageal reflux disease | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02225067 | Aug → Dec 2014 | stomach disorder | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcium (13C)Carbonate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02225067 ↗ |
| Modality | Diagnostic / imaging agent | “C13-CAC breath test” NCT03284177 ↗ |